Ibuprofen in Sepsis Study

This study has been completed.
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:
Vanderbilt University
ClinicalTrials.gov Identifier:
NCT00000574
First received: October 27, 1999
Last updated: January 28, 2016
Last verified: January 2016
  Purpose
To determine the effects of ibuprofen on mortality, development and reversal of shock, and adult respiratory distress syndrome, and on Lung Parenchymal Injury Score in adult patients with serious infection.

Condition Intervention Phase
Acute Respiratory Distress Syndrome
Lung Diseases
Shock, Septic
Drug: ibuprofen
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Vanderbilt University:

Study Start Date: September 1990
Estimated Study Completion Date: July 1995
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
Men and women patients with known or suspected sites of serious infection if core temperature was 38.3 degrees Celsius, heart rate 90 in the absence of beta-blockers, respiratory rate 20 or minute ventilation 10 liters per minute. In addition, one o
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000574

Sponsors and Collaborators
Vanderbilt University
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Investigator: Gordon Bernard Vanderbilt University
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00000574     History of Changes
Other Study ID Numbers: 212  R01HL043167 
Study First Received: October 27, 1999
Last Updated: January 28, 2016
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Acute Lung Injury
Lung Diseases
Respiratory Distress Syndrome, Adult
Respiratory Distress Syndrome, Newborn
Shock, Septic
Infant, Newborn, Diseases
Infant, Premature, Diseases
Infection
Inflammation
Lung Injury
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Sepsis
Shock
Systemic Inflammatory Response Syndrome
Ibuprofen
Analgesics
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents

ClinicalTrials.gov processed this record on April 27, 2016